Kripa Shankar, Nathan P Metzger, Connor Lawrence, Deepali Gupta, Sherri Osborne-Lawrence, Salil Varshney, Omprakash Singh, Corine P Richard, Alexander N Zaykov, Rebecca Rolfts, Barent N DuBois, Diego Perez-Tilve, Bharath K Mani, Suntrea T G Hammer, Jeffrey M Zigman
OBJECTIVE: The number of individuals affected by metabolic dysfunction associated fatty liver disease [1] is on the rise, yet hormonal contributors to the condition remain incompletely described and only a single FDA-approved treatment is available. Some studies suggest that the hormones ghrelin and LEAP2, which act as agonist and antagonist/inverse agonist, respectively, for the G protein coupled receptor GHSR, may influence the development of MAFLD. For instance, ghrelin increases hepatic fat whereas synthetic GHSR antagonists do the opposite...
April 30, 2024: Molecular Metabolism